Cytosorbents Co. (NASDAQ:CTSO) Short Interest Up 5.5% in January

Cytosorbents Co. (NASDAQ:CTSO) was the target of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 1,930,000 shares, a growth of 5.5% from the January 15th total of 1,830,000 shares. Based on an average trading volume of 257,900 shares, the days-to-cover ratio is currently 7.5 days.

Analyst Ratings Changes

CTSO has been the topic of a number of recent research reports. StockNews.com initiated coverage on Cytosorbents in a report on Friday. They issued a “hold” rating on the stock. HC Wainwright restated a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a report on Monday, November 11th. Finally, D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a report on Monday, January 13th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $4.67.

Cytosorbents Stock Performance

Shares of CTSO stock opened at $1.30 on Tuesday. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $1.61. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $71.08 million, a price-to-earnings ratio of -3.61 and a beta of 0.61. The stock’s fifty day simple moving average is $0.99 and its 200-day simple moving average is $1.04.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CTSO. Sargent Investment Group LLC grew its holdings in shares of Cytosorbents by 13.4% during the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after buying an additional 192,747 shares in the last quarter. Avenir Corp grew its holdings in shares of Cytosorbents by 4.0% during the fourth quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock valued at $2,815,000 after buying an additional 118,387 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Cytosorbents during the fourth quarter valued at $99,000. Millennium Management LLC purchased a new position in shares of Cytosorbents during the fourth quarter valued at $30,000. Finally, Geode Capital Management LLC grew its holdings in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after buying an additional 32,415 shares in the last quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.